Creating Value Through Breakthrough Science

We invest in early & late stage companies taking novel scientific approaches to address significant unmet needs in the life sciences and information technology sectors

More Info
Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative

Our Approach

New Science Ventures, LLC (NSV) is a Connecticut and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More

News

November 22, 2024
Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion

Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced approval from the US Food and Drug Administration (FDA) for its allogenic bone grafting material NVDX3 to enter an investigational new drug study (IND). NVDX3 is an allogenic bone grafting material forming a new class of regenerative

Read More
November 19, 2024
Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI

Sagence AI™ has emerged from stealth unveiling a groundbreaking advanced analog in-memory compute architecture that directly addresses the untenable power/performance/price and environmental sustainability conundrum facing AI inferencing. Driven by its industry-first architectural innovations using analog technology, Sagence AI makes possible multiple orders of magnitude improvement in energy efficiency and cost

Read More
October 24, 2024
Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative

Novadip Biosciences, a clinical stage biotechnology company specializing in regenerative medicine, has announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures in adults. Originating from Novadip’s 3M3 platform, NVDX3 is an allogeneic bone grafting material created from human

Read More
October 22, 2024
Phase Four announces monopropellant multi-mode propulsion systems

Phase Four, a leading provider of next-generation electric propulsion (EP) solutions for satellites, has announced the planned commercialization of their monopropellant multimode capability.  Using their Maxwell Block III, Phase Four meets electric propulsion performance for a variety of mission profiles, using either ASCENT or hydrazine chemical propellants. Phase Four anticipates

Read More
October 15, 2024
Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative

Read More
October 1, 2024
Achronix releases groundbreaking Speedster AC7t800 Mid-Range FPGA, driving innovation in AI/ML, 5G/6G and Data Center Applications

Achronix Semiconductor Corporation, a leader in FPGA-based hardware accelerator devices and high-performance eFPGA IP, has announced the availability and shipment of AC7t800 FPGA, designed to address the rapidly growing needs of data-centric applications such as generative AI, DPUs and SmartNICs. With samples available today and units already shipped to customers,

Read More
September 23, 2024
Ventyx Biosciences announces $27 million strategic investment from Sanofi

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of

Read More
September 10, 2024
PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program

PlanetiQ, a leading innovator of global atmospheric observing systems, has been awarded a Delivery Order (DO-4) contract valued at over $6.5M to supply the National Oceanic and Atmospheric Administration (NOAA) with their proprietary radio occultation (RO) data for a period of one year beginning September 18, 2024. “In addition to

Read More
September 6, 2024
Ventyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s

Read More
August 5, 2024
Vascular Therapies completes enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the surgical creation of arteriovenous fistula for hemodialysis vascular access

Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, has announced completion of enrollment in the ACCESS 2 trial, a Phase III prospective randomized, multicenter clinical study of Sirogen™ for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access.

Read More
July 29, 2024
Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in participants with moderately to severely active Crohn’s disease

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of its allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active

Read More
July 17, 2024
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution

Emporos, the industry’s leading Pharmacy Commerce System including Point of Sale (POS), and InterLink AI, creator of scripClip, a state-of-the-art, lighted pharmacy will-call system, are delighted to announce they have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for streamlined prescription will-call, checkout, and

Read More
July 9, 2024
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters

Phase Four, a leading provider of next generation electric propulsion solutions for satellites, proudly announces the signing of a strategic cooperation agreement with Redwire Space (Redwire). This partnership aims to build and deliver Hall Effect Thrusters (HETs) to both government and commercial markets, enhancing the company's capabilities and expanding our

Read More
June 19, 2024
Primemas selects Achronix embedded FPGA technology for System-on-Chip (SoC) Hub Chiplet platform

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Primemas, a fabless semiconductor company developing an innovative SoC Hub Chiplet (Hublet) platform using chiplet technology, has announced a collaboration to bring FPGA programmability to the Primemas suite of products. Primemas chose the Speedcore™ eFPGA IP

Read More
June 5, 2024
Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models. “We are excited by these

Read More
May 13, 2024
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study

Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, has announced the publication of its Phase 2 long COVID results in Clinical Infectious Diseases. The publication entitled “Assessment of the Impact of RNase in Patients with Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2

Read More
April 9, 2024
Finally, Graphene electronic devices available for all

Paragraf, the world’s only mass producer of graphene electronics using transfer-free graphene grown with conventional semiconductor processes, has opened a new online store to enable global access to its unique Graphene-based Field Effect Transistor (“GFET”). GFETs have a wide range of uses in the development of industry, medical, and chemical

Read More
April 4, 2024
DARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations

Phase Four, a leading provider of next generation electric propulsion (EP) solutions for satellites, has been awarded a $14.9M contract by the Defense Advanced Research Projects Agency (DARPA) to deliver an "air-breathing" EP system to enable extended satellite operations in Very Low Earth Orbit (VLEO), at altitudes as low as

Read More
March 26, 2024
Achronix FPGAs add support for Bluespec’s Linux-capable RISC-V Soft Processors to enable scalable processing

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Bluespec, Inc., an industry leader in RISC-V tools and silicon IP, has announced a family of Linux-capable RISC-V soft processors that are available for the Achronix Speedster®7t FPGA family. Marking an industry first, Bluespec’s RISC-V processors

Read More
March 11, 2024
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, have provided clinical and pipeline updates during its virtual investor event. “We are excited to announce clinical updates from our novel

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us

Greenwich

500 West Putnam Avenue, Suite 400, Greenwich CT 06830
T: 212 688 5100 F: 646 844 9845

London

Michelin House, 81 Fulham Road, London SW3 6RD
T: 020 3981 9092